Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 5/20 | 0.49 |
| ▸ | PYGM | P11217 | 5/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 11/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270286 | 1.00 | PYGL (0.49) | PYGLPYGMRIPK1NPC1MAPK13 | |
| SCHEMBL7422479 | 0.87 | PYGL (0.46) | PYGLPYGMRIPK1NPC1MAPK13 | |
| SCHEMBL9025583 | 0.79 | PYGL (0.53) | PYGLPYGMRIPK1NPC1MAPK13 | |
| SCHEMBL9025588 | 0.79 | PYGL (0.53) | PYGLPYGMRIPK1NPC1MAPK13 | |
| SCHEMBL4216634 | 0.78 | PYGL (0.66) | PYGLPYGMRIPK1DDB1CRBN | |
| SCHEMBL4232147 | 0.78 | PYGL (0.66) | PYGLPYGMRIPK1DDB1CRBN | |
| SCHEMBL1976547 | 0.78 | PYGL (0.66) | PYGLPYGMRIPK1DDB1CRBN | |
| SCHEMBL5640452 | 0.77 | PYGL (0.53) | PYGLPYGMRIPK1NPC1MAPK13 | |
| SCHEMBL5640449 | 0.77 | PYGL (0.51) | PYGLPYGMRIPK1NPC1MAPK13 | |
| SCHEMBL9024912 | 0.76 | RIPK1 (0.53) | PYGLPYGMRIPK1NPC1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888345-B2 | Benzaepinones as sodium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181946-A1 | Benzaepinones as Sodium Channel Blockers | TRPV1, TRPA1, KCNN1 | PYGL 4545/4885PYGM 3736/4885RIPK1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.